Literature DB >> 7947081

The treatment of multiple myeloma--an important MRC trial.

P W Johnson, P J Selby.   

Abstract

Entities:  

Mesh：

Year:  1994        PMID： 7947081      PMCID： PMC2033545          DOI： 10.1038/bjc.1994.399

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  79 in total

1.  Circulating malignant precursors in monoclonal gammopathies.

Authors:  F Caligaris-Cappio; L Bergui; G L Gaidano; M Schena; P Putto; F Merico; M Riva
Journal:  Eur J Haematol Suppl       Date:  1989

2.  Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma.

Authors:  X G Zhang; B Klein; R Bataille
Journal:  Blood       Date:  1989-07       Impact factor: 22.113

3.  Multiple myeloma: increased circulating lymphocytes carrying plasma cell-associated antigens as an indicator of poor survival.

Authors:  P Omedé; M Boccadoro; G Gallone; R Frieri; S Battaglio; V Redoglia; A Pileri
Journal:  Blood       Date:  1990-10-01       Impact factor: 22.113

4.  Induction and maintenance therapy in multiple myeloma: a multicenter trial of MP versus VCMP.

Authors:  D Peest; H Deicher; R Coldewey; H J Schmoll; I Schedel
Journal:  Eur J Cancer Clin Oncol       Date:  1988-06

5.  Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy.

Authors:  F Mandelli; G Avvisati; S Amadori; M Boccadoro; A Gernone; V M Lauta; F Marmont; M T Petrucci; M Tribalto; M L Vegna
Journal:  N Engl J Med       Date:  1990-05-17       Impact factor: 91.245

6.  Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants.

Authors:  L B To; M M Roberts; D N Haylock; P G Dyson; A L Branford; D Thorp; J Q Ho; G W Dart; N Horvath; M L Davy
Journal:  Bone Marrow Transplant       Date:  1992-04       Impact factor: 5.483

7.  Serum thymidine kinase as a prognostic indicator for patients with multiple myeloma: results from the MRC (UK) V trial.

Authors:  R D Brown; D E Joshua; M Nelson; J Gibson; J Dunn; I C MacLennan
Journal:  Br J Haematol       Date:  1993-06       Impact factor: 6.998

8.  Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4-hydroperoxycyclophosphamide.

Authors:  D E Reece; M J Barnett; J M Connors; H G Klingemann; S E O'Reilly; J D Shepherd; H J Sutherland; G L Phillips
Journal:  Bone Marrow Transplant       Date:  1993-02       Impact factor: 5.483

9.  High-dose intravenous melphalan for plasma-cell leukaemia and myeloma.

Authors:  T J McElwain; R L Powles
Journal:  Lancet       Date:  1983-10-08       Impact factor: 79.321

10.  A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study.

Authors:  M R Cooper; K Dear; O R McIntyre; H Ozer; J Ellerton; G Canellos; B Bernhardt; D Duggan; D Faragher; C Schiffer
Journal:  J Clin Oncol       Date:  1993-01       Impact factor: 44.544
View more
  1 in total

1.  A prognostic index for multiple myeloma.

Authors:  G Grignani; P G Gobbi; R Formisano; C Pieresca; G Ucci; S Brugnatelli; A Riccardi; E Ascari
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.